IL1B and lung carcinoma: Excitingly, recently published data from the CANTOS study, a randomized trial of the role of IL-1β inhibition in atherosclerosis, suggests that anti-inflammatory therapy targeting the IL-1β pathway could significantly reduce incidence of lung cancer and lung cancer mortality (Ridker et al., 2017b).